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Background: Tobacco smoking is the most important risk factor for chronic obstructive pulmo-
nary disease (COPD) development. Inhaled cigarette smoke can induce tumor necrosis factor-a 
(TNF-a) production by alveolar macrophages, which in turn may enhance the production of 
metalloproteinases (MMPs). MMPs have been involved in mediating airway inflammation and 
lung destruction.
Objectives: We aimed to measure the TNF-a serum levels in healthy heavy smokers and 
healthy nonsmokers to determine the dose-response relationship based on the cigarette smoke 
exposure.
Subjects and methods: We included in our study 43 healthy heavy smokers and 19 healthy 
nonsmokers (the control group). The smokers group was classified as less than one pack, one 
pack, and more than one pack per day. A clinical and paraclinical evaluation was performed 
in both groups, without any evidence of infection or COPD. The serum levels of TNF-a were 
assessed by ELISA.
Results: The TNF-a serum levels were significantly higher for the group of smokers compared 
to the group of nonsmokers (P , 0.004). We also noticed an increased TNF-a concentration in 
the serum of smokers with more than one pack per day compared with those with less than one 
pack per day (P , 0.03). There was a positive correlation between the serum level of TNF-a 
and tobacco smoke exposure.
Conclusions: The high levels of TNF-a in the serum of smokers suggest an imbalance between 
the proinflammatory and anti-inflammatory factors as a result of tobacco smoke exposure. The 
concentration of TNF-a is elevated in the serum of healthy heavy smokers in a cigarette dose-
dependent manner. We speculate that the serum level of TNF-a might be a useful biomarker 
for the selection of heavy smokers with a high risk of developing smoke induced pulmonary 
diseases.
Keywords: tobacco smoking, inflammation, chronic obstructive pulmonary disease, 
metalloproteinases
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by an airflow limitation 
that is not completely reversible. It is a heterogeneous disease involving both airways 
and pulmonary parenchyma. An abnormal inflammatory response of the lung to dif-
ferent noxious compounds (tobacco smoke, occupational and environmental noxious 
substances) can also be observed. COPD is an important public health issue, the World 
Health Organization (WHO) estimating around 210 million cases worldwide in 2007. 
It is expected to become the third leading cause of death by 2030.1International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Although extensively studied, the underlying mechanisms 
of COPD development are not fully understood. The wide 
variety of inflammatory cells and mediators that have been 
found at increased levels in COPD patients2,3 suggests the 
major role of the inflammatory process triggered by various 
noxious agents, like tobacco smoke. In most world regions, 
tobacco smoke is by far the most communally encountered 
risk factor for COPD. However, although not all heavy 
smokers develop the disease, the absolute risk exceeds 25%.4 
This individual variability suggests the intervention of dif-
ferent genetic, epigenetic, and environmental factors that 
act synergistically to determine the overall risk of COPD. 
Alpha1-antitrypsin deficiency is the best documented genetic 
risk factor for COPD development, but it accounts for only 
1%–2% of all cases.5 Tumor necrosis factor-a (TNF-a) 
gene polymorphism is another genetic factor that might 
determine the susceptibility to COPD.6 The above data are 
also supported by the observation that TNF-308A allele has 
been associated with an increased transcriptional activity 
in various diseases.7,8 TNF-a was originally described as a 
factor produced by the endotoxin stimulated macrophages 
that causes hemorrhagic necrosis of tumors.9 It is a powerful 
proinflammatory cytokine with pleiotropic properties and a 
key mediator of inflammation. TNF-a operates by binding 
to two structurally related cell surface receptors: p55 and 
p75. However, the p55 receptor seems to be responsible for 
mediating the majority of TNF-a function.10,11 Both receptors 
can be proteoliticaly cleaved and released as soluble forms, a 
good marker of TNF-a activation. TNF-a is one of the most 
extensively studied cytokines in COPD. An increased level of 
TNF-a has been found in induced sputum or lung biopsy 
of COPD patients.12–14 In a rat model of COPD, high levels 
of TNF-a have also been observed in the bronchoalveolar 
lavage fluid and serum, suggesting the important role of this 
cytokine in the initiation and progression of the inflamma-
tory process of the lung.15 Although TNF-a inhibitors had no 
clinically beneficial effects in COPD patients,16 a recent study 
demonstrated a significant reduction of the smoke-induced 
alveolar septal tissue destruction in rats.17
Various studies suggest that TNF-a and its receptors could 
be useful biomarkers with a potential prognostic value in 
several diseases associated with local and systemic inflam-
mation. Moreover, a recent study also found a significant 
increase in the serum p75 receptor levels in patients with 
peripheral arterial disease.18 Important evidence also suggests 
that cigarette smokers are at higher risk of inflammatory 
cardiovascular disease when compared to nonsmokers.19 
Tappia et al showed that TNF-a production in the blood 
from smokers exposed to endotoxin was 38% higher than in 
nonsmokers.20 It is now accepted that COPD is a prevent-
able condition, and only a protportion of heavy smokers 
develop the disease. Therefore, there is a need to identify 
new biomarkers which could assess the individual risk of 
the disease in order to increase the efficacy of primary and 
secondary prevention. Considering the above evidence, we 
hypothesize that TNF-a might be a useful biomarker to assess 
airways’ inflammation and the risk of developing COPD in 
heavy smokers. In this study we aimed to assess the serum 
levels of TNF-a in healthy heavy smokers and nonsmokers, 
and to find a correlation between TNF-a serum level and 
quantity of smoking.
Subjects and methods
subjects
We designed an observational, prospective, cohort study: 
43 healthy smokers and 19 healthy nonsmokers were ran-
domly included. All were of Caucasian origin. We enrolled 
smokers that had registered for a smoking cessation program 
for the first time. The control group comprised healthy hos-
pital workers who had never smoked. As the study group 
was not sufficiently large to eliminate the sex differences, 
all subjects were male. Informed consent was obtained from 
each subject before inclusion (a comprehensive description of 
the study was previously provided). The study was approved 
by the Ethical Committee of the University of Medicine and 
Pharmacy of Craiova, Romania.
A detailed medical history, physical examination, and 
blood tests were performed. Both smokers and nonsmok-
ers had no evidence of any significant disease (including 
chronic bronchitis). In order to minimize the influence of 
other factors, each subject had to fulfill the following inclu-
sion criteria: 1. absence of any systemic disease, including 
autoimmune diseases; 2. absence of any infection during the 
previous two months; 3. body mass index (weight in kg 
divided by the square of height in m) ,25 kg/m2; 4. no his-
tory of chronic alcohol abuse; 5. absence of any drug intake 
during the previous 3 months (including medication for 
acute medical conditions, as the common cold). We used two 
additional inclusion criteria for the smoker group: 1. smoking 
history of at least 20 pack-year, and 2. smoking habit of at 
least 10 cigarettes per day. Former smokers were excluded. 
Nonsmokers were defined as zero cigarettes lifelong. A total 
number of 62 participants were approached initially, but 
19 participants were excluded for different reasons:   presence 
of comorbidities (hypertension in five subjects; chronic viral 
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renal failure in 1 subject), drug intake during the previous 3 
months (four subjects), overweight (two subjects), alcohol 
abuse (two subjects), light smoking history (two subjects).
Pulmonary function tests
Forced expiratory volume in one second (FEV1) and forced 
vital capacity (FVC ) were measured with standard spiromet-
ric techniques. Both smokers and nonsmokers had normal 
spirometric parameters.
Methods
The venous blood samples were drawn in the morning between 
7:30 and 8:00 AM, after an overnight fast and before the first 
morning cigarette. They were immediately centrifuged at 
1500 rpm for 10 minutes; the plasma was stored at -20°C until 
analyzed. The serum levels of TNF-a were performed with a 
commercially available ELISA kit, following the instructions 
provided by the manufacturer (DRG Diagnostics, Germany).
statistical analysis
Data are expressed as mean ± standard deviation (SD). The 
comparison of variables between our groups of subjects 
was performed using the Student’s t-test. A P value below 
0.05 was considered statistically significant. The Pearson’s 
correlation technique was used to evaluate the associations 
between variables.
Results
The characteristics of the study groups are shown in the 
Table 1. The average age of our subjects was not significantly 
different between the groups. The smoker group had a signifi-
cantly higher serum level of C-reactive protein (CRP).
The serum levels of TNF-a were significantly higher in 
the smoker group than in the nonsmoker group (P , 0.004; 
Figure 1). We then divided our smoker group into smokers 
of less than 1 pack/day (16 subjects) and smokers of more 
Table 1 The characteristics of our smokers and nonsmokers group
Smokers Nonsmokers P value
Age (years) 52.06 ± 5.86 55.21 ± 8.5 ns
Male sex (%) 100 100 ns
Pack-year 30.16 ± 10.02 – –
Pack/day 1.07 ± 0.37 – –
BMI (Kg/m2) 22.01 ± 1.64 21.78 ± 1.84 ns
Alcohol consumption  
(g/day)
27.53 ± 10.92 24 ± 11.73 ns
CrP (mg/L) 12.81 ± 9.72 8.42 ± 5.87 ,0.05
Note: Mean ± sD.
Abbreviations: NS, not significant; BMI, body mass index; CRP, C-reactive protein.
T
N
F
-
α
 
s
e
r
u
m
 
l
e
v
e
l
 
(
p
g
/
m
L
)
60
50
40
30
20
10
0
Nonsmokers Smokers
Figure  1  The  tumor  necrosis  factor-a  (TnF-a)  serum  levels  in  smokers  and 
nonsmokers (P , 0.004).
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Figure 2 Tumor necrosis factor-a (TnF-a) serum levels in smokers, according to 
their daily smoking exposure (P , 0.03).
than 1 pack/day (18 subjects). We found a significantly higher 
serum level of TNF-a in subjects that smoked more than 1 
pack/day (P , 0.03; Figure 2). When we further compared 
the concentration of TNF-a in the serum of nonsmokers 
and smokers with a daily exposure of less than 1 pack, the 
between-group difference did not reach statistical signifi-
cance (P = 0.17; Figure 3).
There was a positive correlation between the levels of 
TNF-a in the serum of our smoker subjects and the total 
smoking exposure (quantified as pack-year), the daily smoking 
exposure (quantified as pack/day) and the CRP serum levels 
(r = 0.591, r = 0.395, and r = 0.506, respectively; Figure 4).
Discussion
The main finding of our study was the high serum level of 
TNF-a in healthy heavy smokers compared to   nonsmokers. International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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To the best of our knowledge, this is the first study that 
demonstrates a clear difference in TNF-a serum levels 
between smokers and nonsmokers. Zoppini and cowork-
ers21 reported that type 1 diabetic smokers had increased 
serum levels of the p55 receptor compared to healthy non-
smokers or diabetic nonsmokers. Another study conducted 
by Fernandez-Real et al22 showed that circulating levels of 
p75 receptors were significantly higher in healthy smok-
ers than in nonsmokers, despite the lower fat mass in the 
smoker group. Both soluble TNF-a receptors (sTNFRs), 
p55 and p75, are increased in the serum of patients with 
different inflammatory diseases.23 TNF-a degradation is 
significantly delayed in the presence of its soluble recep-
tors which suggests that sTNFRs could be a more sensitive 
marker of activation of the TNF-a system.24 Our findings 
are also supported by the observations of Boström et al25 
who reported an increased level of TNF-a in the gingival 
crevicular fluid of smoker patients compared to non-
smoker patients with periodontal disease. In contrast to 
our results, Kuschner and coworkers26 showed that TNF-a 
levels were not significantly different between healthy 
smokers and nonsmokers in bronchoalveolar lavage 
fluid. However, both research group size and smoking 
exposure were smaller in their study, aspects that might 
explain the contrasting results. A recent study conducted 
by Diez-Pina et al27 reported that male smokers had higher 
TNF-a levels than male nonsmokers in the exhaled breath 
condensate, which may signal the presence of a smoke-
induced inflammatory process in the lungs of healthy 
subjects. The smoke-induced inflammatory response could 
also vary depending upon gender or ethnicity. Some stud-
ies have already shown that tobacco smoke effects might 
be sex- and race-dependent.28,29 We were not able to verify 
the influence of these two factors on the serum levels of 
TNF-a due to the small size of our study group.
The major role of TNF-a in smoke-induced lung injuries 
is supported by a large number of studies. It was reported 
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Figure  3  Tumor  necrosis  factor-a  (TnF-a)  serum  levels  in  nonsmokers  and 
smokers with less than 1 pack/day smoking exposure (P , 0.17).
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Figure 4 The serum levels of tumor necrosis factor-a (TnF-a) and total smoking 
exposure were positively correlated (A). A positive correlation could also be seen 
between the TnF-a serum levels, the daily smoking exposure and the C-reactive 
protein (CrP) serum levels (B,C).
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that TNF-a overexpression induced   histological features 
of both emphysema and pulmonary fibrosis in transgenic 
mice.30 A recent study conducted by D’hulst and coworkers31 
demonstrated that p75 receptor knockout mice were protected 
against cigarette smoke induced pulmonary emphysema. The 
authors also showed that cigarette smoke exposure increased 
the inflammatory infiltrate in the bronchoalveolar lavage 
fluid of wild type, p55 knockout or p75 knockout mice, 
in comparison with air-exposed mice. However, both p55 
and p75 knockout mice showed weaker lung inflammation, 
suggesting the major role of TNF-a system in the media-
tion of smoke-induced lung injury. Other authors reported 
a significant increase in the mRNA expression of TNF-a in 
the lungs of guinea pigs following a single dose exposure 
to cigarette smoke.32 The components of cigarette smoke 
that are responsible for the local and systemic inflamma-
tory response have not been fully elucidated. The bacterial 
endotoxin contained in tobacco can survive combustion as 
an active compound of tobacco smoke.33 Thus, it might be 
one of the many pathologic substances involved in cigarette 
smoke-induced inflammatory reaction.
We showed a further increase of TNF-a serum levels in 
patients who had a daily smoke exposure of more than 1 pack/
day. There was no significant difference between the serum 
levels of TNF-a of nonsmokers and those who smoked less 
than 1 pack daily. This observation might suggest that the 
smoke-induced activation of inflammation usually requires a 
significant amount of exposure. The serum levels of TNF-a 
were also positively correlated with the total smoke exposure 
(pack-year), the daily smoke exposure (pack/day) and the 
CRP serum levels. Our findings are in agreement with the 
observations of Zoppini et al21 who demonstrated a marked 
increase of TNF-a system activation with an increase in the 
number of cigarettes smoked per day. Similar results were 
reported by Fernandez-Real and coworkers.22
In conclusion, we found that heavy smoking could induce 
a significant increase in serum TNF-a and CRP levels, sug-
gesting the imbalance between the proinflammatory and 
antiinflammatory factors. The concentration of TNF-a was 
elevated in the serum of healthy heavy smokers in a dose 
dependent manner. Based on our findings and the other 
data in the literature, we speculate that the serum levels of 
TNF-a and CRP might be useful biomarkers for the selec-
tion of heavy smokers with a high risk of developing smoke 
induced pulmonary diseases. Further studies are necessary 
to evaluate the prognostic value of these markers in a large 
population group. It would also be interesting to assess the 
correlation between the serum levels of TNF-a or CRP and 
the airways inflammation of this group of subjects. Future 
studies will have to focus on additional potential markers 
in order to develop a specific biomarker panel to assess the 
tobacco smoke susceptibility of healthy smokers.
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